TEM-1 and TEM pUC19 b-lactamases can gain activity against ceftazidime and other expandedspectrum cephalosporins via point mutation. The frequency of emergent resistance to ceftazidime at 4 · MIC was elevated ‡ 250-fold in hyper-mutable, MutS-deficient Escherichia coli harbouring these b-lactamase genes on high-or low-copy plasmids. Moreover, although ceftazidime-resistant mutants, or those with reduced susceptibility, were selected in both the wild-type and mutS hosts, many more mutants in the mutS host showed ceftazidimase-type extended-spectrum b-lactamase (ESBL) activity. This correlated with a G-A point mutation at position 484 in the bla TEM-1 and bla TEM-pUC19 genes, conferring the Arg164His amino-acid substitution found in the TEM-29 ESBL. Non-ESBL mutants lacked changes in bla TEM .
An elevated mutation frequency in wild populations of Escherichia coli is associated most often with lesions in the DNA repair pathway gene mutS [1], which is responsible for post-replicative DNA repair. Such lesions can modulate the chromosomal mutation frequency by up to 1000-fold [2] , and it has been suggested that the emergence of resistance from plasmid-borne genes should also be increased [3] . This may be relevant to the evolution of extended-spectrum [4] and inhibitor-resistant variants of TEM and SHV b-lactamases. Although CTX-M-type extendedspectrum b-lactamases (ESBLs) are now more prevalent than TEM-and SHV-ESBLs in Asia and Europe [5, 6] , the latter remain the main ESBL types in the USA and are common elsewhere [7] , with over 190 variants described to date (http:// www.lahey.org/studies/webt.htm). Amino-acid substitutions at a limited number of residues can critically extend the substrate range, with substitutions at positions 104, 238 and 164 being particularly important in the TEM family [8] .
A few studies have examined the role of mutators in the evolution of ESBL activity [9, 10] but, to date, TEM-ESBL development has been studied only in a dnaQ E. coli mutator strain [10] . In contrast to mutS [1], no wild-type isolates with lesions in dnaQ have been described. The present study examined the effect of mutS-mediated hyper-mutability on the development of ceftazidimase activity in TEM-1-type penicillinases in wild-type and MutS-negative E. coli strains carrying a bla TEM gene on either (1) a low-copynumber plasmid, as is the case for most TEM-encoding R plasmids, or (2) high-copynumber pUC19-type plasmids [11] .
The pUC19-encoded b-lactamase TEM pUC19 differs from classic TEM-1 by two amino-acid substitutions, Val84Ile and Ala184Val, on the 515-bp XmnI and BsrFI fragment of pUC19. For part of this study, this fragment was excised and replaced by the corresponding fragment of TEM-1 from plasmid pBR322. Transformants were selected on nutrient agar containing ampicillin 100 mg ⁄ L and were checked by sequencing the bla TEM gene on both strands using a CEQ 8000 DNA sequencer (Beckman-Coulter, High Wycombe, UK). The resulting plasmid was designated pTEM-1.
High-copy-number plasmids pUC19 and pTEM-1, and low-copy-number plasmid pBR322, were each electroporated into electrocompetent cells of strains 1411 (wild-type) and 1413 (mutSnegative) [12] . Transformants were selected on nutrient agar containing ampicillin 100 mg ⁄ L, and the bla TEM genes were sequenced. MICs were determined by Etest (AB Biodisk, Solna, Sweden) on IsoSensitest agar or by agar dilution on IsoSensitest agar [13] . None of these plasmids caused any significant increase in the MIC of ceftazidime.
Selection of mutants was performed on nutrient agar containing ceftazidime at 4 · MIC in triplicate experiments from three independent cultures. Inocula comprised 10 9 CFU from overnight nutrient broth cultures grown from single colonies. Plates were incubated aerobically at 37°C for 18 h, after which the colonies were counted. Mutants resistant to ceftazidime at 4 · MIC were obtained from the mutS strain harbouring the high-copy-number plasmids pTEM-1 or pUC19 c. 250-fold and > 300-fold more frequently than from the corresponding wild-type strain carrying these same plasmids (Table 1) , but the emergence of ceftazidime resistance was at an order of magnitude lower in both hosts harbouring pBR322, as compared with the higher-copynumber vectors. Nevertheless, a differential of c. 300-fold was still observed between transformants of the wild-type and mutS strains (Table 1) .
Randomly selected mutants from separate experiments with each of the six host strainplasmid combinations were chosen in roughly equal proportions for MIC determinations (Table 2 ). In the mutS host, 17 pTEM-1, 15 pUC19 and 18 pBR322 mutants had ceftazidime MICs of 2-16 mg ⁄ L (pUC19 and pBR322 mutants) and 2-64 mg ⁄ L (pTEM-1 mutants) ( Table 2 ). All 50 mutants had decreased susceptibility to cefepime, and showed ‡ 8-fold potentiation of ceftazidime in the presence of clavulanate (Table 2) , suggesting the development of ESBL activity.
All of the mutants selected from transformants of the non-hyper-mutable strain containing pUC19 or pTEM-1 (n = 28) had decreased susceptibility to ceftazidime, but remained susceptible to £ 1 mg ⁄ L. Moreover, there was < 8-fold potentiation of ceftazidime by clavulanate for these mutants, suggesting that they lacked ESBL activity. Among 13 mutants of the wild-type host (1411) containing the lower-copy-number plasmid pBR322, four had ceftazidime MICs of 4 mg ⁄ L, and two of these showed > 8-fold potentiation of ceftazidime by clavulanate, implying ESBL activity.
From each of the six host-plasmid combinations, 30 ceftazidime-selected mutants of pUC19, pTEM-1 and pBR322 bla TEM genes were sequenced. The latter 30 comprised 15 wild-type and 15 mutS variants; two of the former and 12 of the latter had ESBL phenotypes. All 12 mutants with ESBL phenotypes (three, five and four derived from pUC19, pTEM-1 and pBR322, respectively) harboured TEM genes carrying a G-A point mutation at nucleotide 484 of the bla TEM open reading frame, resulting in an Arg164His amino-acid substitution. This change is known to confer ESBL activity [14] , changing TEM-1 into TEM-29. Both wild-type (1411) mutants with an ESBL phenotype harboured pBR322 that encoded TEM-29. Upon re-transformation into fresh host cells, plasmids encoding TEM-29 conferred identical MIC profiles to those of the original mutants, indicating that the observed resistances were mediated by the plasmid alone.
The ESBL-negative mutants selected from strain 1411 harbouring pTEM-1, pUC19 or pBR322 showed up to eight-fold reductions in ceftazidime susceptibility, although MICs did not exceed the BSAC resistance breakpoint of 2 mg ⁄ L [13] (Table 2) . No increase in AmpC b-lactamase activity was detected with a cloxacillin potentiation test comparing zones around 30-lg cefotaxime and 30-lg ceftazidime disks (Oxoid, Basingstoke, UK) on IsoSensitest agar with and without cloxacillin 100 mg ⁄ L. However, these variants had up to eight-fold decreased susceptibility to cefoxitin, tetracycline and ciprofloxacin, as well as decreased OmpF expression following SDS-PAGE analysis (data not shown). The disparity in the number of ESBL and OmpF mutants selected among the MutS and wild-type hosts, and the lack of mutants hyper-expressing the chromosomal AmpC b-lactamase, could be caused by differences in the fitness cost of each type of mutation. The mutation frequency for resistance to ceftzidime at 4 · MIC and 1 mg ⁄ L for the plasmid-free wild-type (1411) and mutS (1413) strains was 180-fold higher in the mutS host at 4 · MIC of ceftazidime (Table 1) . At 1 mg ⁄ L, it was only possible to select mutants from the mutS strain. Elevated MICs of ceftazidime, cefoxitin, tetracycline and ciprofloxacin were observed for the mutants (Table 2) , suggesting changes to cell impermeability or efflux systems.
In summary, these experiments indicate the potential of hyper-mutators to extend the hydrolysis spectra of TEM b-lactamases encoded by high-and low-copy-number plasmids. An Arg164His change was detected in the ESBL mutants generated from pUC19, pTEM-1 and pBR322. In the case of pTEM-1 and pBR322, this changed TEM-1 into the TEM-29 ESBL [15] . The same substitution is present in c. 10% of the different TEM-ESBL variants described to date (http://www.lahey.org/studies/webt.htm), and TEM-29 may have been a progenitor for the development of further variants, perhaps facilitated by mutator hosts. In contrast, the wild-type strain with TEM-encoding plasmids yielded mostly mutants with changes in the host chromosome rather than bla TEM .
The observation of mutator strains among natural E. coli populations [1], and their increased prevalence among ESBL-producing urinary tract isolates [16] , raises the possibility that TEM-ESBLs may also evolve in mutator strains. This may explain the frequent association between ESBL activity and other resistances contingent upon mutation, e.g., that to fluoroquinolones [17] . 
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